Cytolytic peptides have commanded attention for their anticancer potential because the
membrane-disrupting function that produces cell death is less likely to be overcome by
resistant mutations. Congruently, peptides that are involved in molecular recognition and
biological activities become attractive therapeutic candidates because of their high
specificity, better affinity, reduced immunogenicity, and reduced off target toxicity. However,
problems of inadequate delivery, rapid deactivation in vivo, and poor bioavailability have …